Perspectives on Food, Drug, Medical Device & Cosmetic
236 total results. Page 2 of 10.
Join ArentFox Schiff Partners Stephanie Trunk, a recognized authority in government pricing and compliance, and Jacques Smith, a leading health care litigator with extensive experience guiding life science companies through government inquiries, as they share key insights and aim to equip participants with the knowledge to effectively manage due diligence in life science mergers and acquisitions.
Under current US Food and Drug Administration (FDA) guidance, sexually active gay and bisexual men are prohibited from anonymously donating sperm.
License Exception MED, published by the US Department of Commerce’s Bureau of Industry and Security (BIS) on April 25, authorizes the export, reexport, or in-country transfer of EAR99 “medical devices” to non-military hospitals but comes with new restrictions and due diligence requirements.
In an industry known for its fast-paced changes, 2024 will be no different for cannabis.
Two bills, quite different in scope but both aiming to further restrict the use or presence of per-and polyfluoroalkyl substances (PFAS) in various products, are currently wending their way through the California legislature.
FDA Practice Leader and AgTech Industry Group Co-Leader Karen Carr will speak on a panel on treated seeds at the 2024 CropLife America and RISE Spring Regulatory Conference on April 17, 2024.
Welcome to the April 2024 issue of “As the (Customs and Trade) World Turns,” our monthly newsletter where we compile essential updates from the customs and trade world over the past month.
Since January 1, 2022, California’s Fragrance and Flavor Ingredients Right to Know Act of 2020 has required manufacturers of cosmetic products to disclose the following information to the California Department of Public Health (CDPH):
PFAS are a large family of synthetic organic chemicals containing carbon chains in which most or all of the hydrogen atoms have been replaced by fluorine.
The Federal Communications Commission (FCC) has announced the new members of the four “Working Groups” that will continue to assist its Precision Agriculture Connectivity Task Force.
ArentFox Schiff will host the Food Policy Impact Summit at our Washington, DC, office on February 27-28, 2024. FDA Practice Leader Karen Carr and Partner Rachel Remke will present on timely developments impacting the food and nutrition regulatory landscape.
2023 was a pivotal year for the beverage and food industry globally, creating new categories of winners and losers across the board. With a full year of operations largely relieved of pandemic-era restrictions, restaurant companies that survived the pandemic posted record numbers.
On January 30, a federal jury found six people guilty of federal civil rights offenses arising from their participation in a blockade of a reproductive health care clinic in Mount Juliet, Tennessee.
Food, Drug, Medical Device & Cosmetic Associate Shoshana Golden will give a presentation on the Modernization of Cosmetics Regulation Act of 2022 (MoCRA) and the intricate regulatory landscape governing cosmetics and over-the-counter (OTC) drugs at the American Conference Institute’s (ACI) Advanced Legal, Regulatory, and Compliance Forum on Over-the-Counter Drugs in New York City on January 23-24, 2024.
ArentFox Schiff is pleased to announce the selection of Brian P. Waldman as Firmwide Managing Partner, effective January 1, 2024.
On December 18, the US Food and Drug Administration (FDA) announced the availability of the Cosmetics Direct electronic submission portal and publication of final guidance for industry on cosmetic facility registration and cosmetic product listing.
On December 14, the US Food and Drug Administration (FDA) issued new instructions for cosmetic companies to use when submitting mandatory serious adverse event reports to the agency.
What do eggnog, Christmas pudding, gingerbread cookies, and fruit cake all have in common? Cinnamon. But this year, the spice giving these desserts their holiday cheer could also come with a toxic level of lead.
A major new research paper has concluded what many doctors had long believed was true – that patients can be switched between reference (or name brand) biologics and biosimilars with no issues involving the safety profiles or immunogenicity rates of the two drugs.
On November 8, the US Food and Drug Administration (FDA) announced its intent to delay enforcement of the requirements for cosmetic product facility registration and cosmetic product listing.
ArentFox Schiff has been awarded 62 top rankings in the 2024 edition of Best Law Firms® which recognizes firms for professional excellence based on consistently positive ratings from clients and peers.
On October 7, California Governor Gavin Newson signed into law AB-418, the California Food Safety Act, which completely bans, on safety grounds, the use in food of four additives that are considered safe by the US Food and Drug Administration (FDA). The ban becomes effective January 1, 2027.
On October 3, the US Food and Drug Administration (FDA) issued a proposed rule regarding the regulation of in vitro diagnostic products (IVDs).
Last Friday, the US Food and Drug Administration (FDA) announced its newly developed draft electronic submission portal — Cosmetics Direct — to facilitate submissions of cosmetic product facility registrations and product listings later this year.
The US Food and Drug Administration (FDA) has just issued a draft guidance entitled “Best Practices for Selecting a Predicate Device to Support a Premarket Notification 510(k) Notification.”